OTC Markets OTCPK - Delayed Quote USD

Nexien BioPharma, Inc. (NXEN)

0.0100
0.0000
(0.00%)
At close: May 16 at 4:00:00 PM EDT
Loading Chart for NXEN
  • Previous Close 0.0000
  • Open 0.0140
  • Bid 0.0095 x --
  • Ask 0.0145 x --
  • Day's Range 0.0140 - 0.0140
  • 52 Week Range 0.0040 - 0.0500
  • Volume 11,467
  • Avg. Volume 2,939
  • Market Cap (intraday) 707,722
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0000
  • Earnings Date May 14, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Nexien BioPharma, Inc. focuses on the formulation, development, and commercialization of cannabinoid-based pharmaceuticals, drug delivery systems, and related technologies for diseases, disorders, and medical conditions in the United States. The company was formerly known as Intiva BioPharma Inc. and changed its name to Nexien BioPharma, Inc. in September 2018. Nexien BioPharma, Inc. is based in Glendale, Colorado.

www.nexienbiopharma.com

--

Full Time Employees

June 30

Fiscal Year Ends

Recent News: NXEN

View More

Performance Overview: NXEN

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NXEN
66.67%
S&P 500 (^GSPC)
1.30%

1-Year Return

NXEN
44.44%
S&P 500 (^GSPC)
12.48%

3-Year Return

NXEN
84.13%
S&P 500 (^GSPC)
48.66%

5-Year Return

NXEN
67.74%
S&P 500 (^GSPC)
108.07%

Compare To: NXEN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: NXEN

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    686.49k

  • Enterprise Value

    1.04M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -655.83%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -188.08k

  • Diluted EPS (ttm)

    -0.0000

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.29k

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    57.49k

Research Analysis: NXEN

View More

Company Insights: NXEN

Research Reports: NXEN

View More

People Also Watch